A Phase 1 interventional study of Brimonidine tartrate in Hyperemia, sponsored by Bausch & Lomb Incorporated. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-28.
Sponsored by Bausch & Lomb Incorporated (part of Bausch Health Companies Inc.) · Phase 1, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Hyperemia with a site in United States — 9 open to participants now, 9 under way, 2 of them phase 3. Hyperemia · United States.
Among the 23 studies in Hyperemia with a site in United States, this one is the 17th largest by enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2014, is one of 3 in phase 1, and was the 5th registered.
98 studies on the registry are indexed under Hyperemia; 44 are open to participants now.
Browse Hyperemia studies →9 of the 23 studies in Hyperemia with a site in United States are open now. Recruiting first, the newest first:
Alcon Research · Sites in United States
Ages 18+
Alcon Research · Sites in United States
Ages 18+
Insight Eyecare Specialties, Inc. dba Vision Source Eyecare, · Sites in United States
Ages 18–65 · Healthy volunteers
Georgia State University · Sites in United States
Ages 20–59
Georgia State University · Sites in United States
Ages 20–65 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 28 Hyperemia studies recruiting now, 17 (61%) set no upper age limit and 7 (25%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 4 · Phase 3 6 · Phase 4 2
First in 2008; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 68 across 51 interventional studies indexed under Hyperemia.
Median enrollment 68 across the 19 interventional studies, 40 across the 4 observational. Of the 14 that completed or were terminated, 8 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 23 have an industry lead sponsor. The 10 most frequent:
This study is registered under Bausch & Lomb Incorporated, one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Bausch & Lomb Incorporated is the lead sponsor of 223 studies on the registry; 5 are open to participants now.
Of its 51 completed or terminated interventional studies of FDA-regulated products, 41 (80%) have results posted.
Bausch Health Companies Inc. has 3 studies filed under Hyperemia — fewer than ten, so there is no comparison to draw.
6 of the studies in Hyperemia with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07578363Phase 3Alcon ResearchAn Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness in Adults | 2026-11 |
| NCT07531043Phase 3Alcon ResearchEfficacy and Safety of FID 123472 Ophthalmic Solution for Ocular Redness in Adults | 2027-02 |
| NCT07209410Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma | 2026-12-15 |
| NCT06735599Georgia State UniversityWild Blueberries for Gut, Brain, and Heart Health in Adults With High Blood Pressure | 2027-01-01 |
| NCT06735651Georgia State UniversityWild Blueberries for Gut, Brain, and Cardiometabolic Health in Prediabetes | 2027-06-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 23 studies in Hyperemia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To characterize the plasma pharmacokinetics and safety profile of brimonidine following a single dose and 4 times per day (QID) dosing of brimonidine tartrate ophthalmic solution 0.025% for 7 days in healthy, adult subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One drop of brimonidine tartrate ophthalmic solution 0.025% in each eye once at Visit 2 (Day 1) then four times daily (QID) approximately 4 hours apart at Visit 3 (Day 2) through day 6, and then once at Visit 4 (Day 7).
Drug: Brimonidine tartrate
Plasma Levels
Blood samples will be collected for the determination of brimonidine in plasma at the specified time points on Day 1.
Time frame: Day 1 (Visit 2)
Plasma Levels
Blood samples will be collected for the determination of brimonidine in plasma at the specified time points on Day 2.
Time frame: Day 2 (Visit 3)
Plasma Levels
Blood samples will be collected for the determination of brimonidine in plasma at the specified time points on Day 7.
Time frame: Day 7 (Visit 4)
Plasma Levels
Blood samples will be collected for the determination of brimonidine in plasma at the specified time points on Day 8.
Time frame: Day 8 (Visit 5)
Visual Acuity
Visual acuity testing should be done with best correction at 10ft
Time frame: Baseline (Visit 1)
Slit Lamp Biomicroscopy
Lid and lid margin erythema and swelling, conjunctival erythema/hyperemia and chemosis will be graded on a scale of 0 - 4. with 0=normal and 4=marked. Half grade measurements will be accepted for erythema/hyperemia.
Time frame: Baseline (Visit 1)
Intraocular Pressure
Intraocular Pressure measured at baseline Day 8 (Visit 5)
Time frame: Day 8 (Visit 5)
Hematology and Blood Chemistry Analysis
Blood samples will be collected for hematology and blood chemistry parameters at Baseline (Visit 1)
Time frame: Baseline (Visit 1)
Urinalysis
Urine sample will be collected for urinalysis at Baseline (Visit 1)
Time frame: Baseline (Visit 1)
Visual Acuity
Visual acuity testing should be done with best correction at 10ft
Time frame: Day 1 (Visit 2)
Visual Acuity
Visual acuity testing should be done with best correction at 10ft
Time frame: Day 7 (Visit 4)
Visual Acuity
Visual acuity testing should be done with best correction at 10ft
Time frame: Day 8 (Visit 5)
Slit Lamp Biomicroscopy
Lid and lid margin erythema and swelling, conjunctival erythema/hyperemia and chemosis will be graded on a scale of 0 - 4. with 0=normal and 4=marked. Half grade measurements will be accepted for erythema/hyperemia.
Time frame: Day 1 (Visit 2)
Slit Lamp Biomicroscopy
Lid and lid margin erythema and swelling, conjunctival erythema/hyperemia and chemosis will be graded on a scale of 0 - 4. with 0=normal and 4=marked. Half grade measurements will be accepted for erythema/hyperemia.
Time frame: Day 7 (Visit 4)
Slit Lamp Biomicroscopy
Lid and lid margin erythema and swelling, conjunctival erythema/hyperemia and chemosis will be graded on a scale of 0 - 4. with 0=normal and 4=marked. Half grade measurements will be accepted for erythema/hyperemia.
Time frame: Day 8 (Visit 5)
Intraocular Pressure
Intraocular Pressure measured at baseline (Visit 1)
Time frame: Baseline (Visit 1)
Hematology and Blood Chemistry Analysis
Blood samples will be collected for hematology and blood chemistry parameters at Day 8 (Visit 5)
Time frame: Day 8 (Visit 5)
Urinalysis
Urine sample will be collected for urinalysis at Day 8 (Visit 5)
Time frame: Day 8 (Visit 5)
Ran from Feb 2014 to primary completion in Mar 2014, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brimonidine